Results of the Prolonged Use of Subcutaneous Continuous Infusion of Hydrocortisone in a Man with Congenital Adrenal Hyperplasia by Sonnet, Emmanuel et al.
International Scholarly Research Network
ISRN Endocrinology
Volume 2011, Article ID 219494, 4 pages
doi:10.5402/2011/219494
Case Report
ResultsoftheProlonged Use ofSubcutaneous
ContinuousInfusionof Hydrocortisone ina Man with
CongenitalAdrenalHyperplasia
EmmanuelSonnet,NathalieRoudaut,andV´ eroniqueKerlan
Service d’Endocrinologie, Hˆ opital de la Cavale Blanche CHU de Brest, Boulevard Tanguy Prigent, 29609 Brest Cedex, France
Correspondence should be addressed to Emmanuel Sonnet, emmanuel.sonnet@chu-brest.fr
Received 24 December 2010; Accepted 16 February 2011
Academic Editors: M. De Rosa, J. A. Rillema, and J. W. Tomlinson
Copyright © 2011 Emmanuel Sonnet et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
This is a case report study of a young man with Congenital Adrenal Hyperplasia (CAH) who has been treated during 2 years
by a subcutaneous continuous infusion hydrocortisone (SCIH) to optimize his treatment. Hydrocortisone was delivered via an
insulin infusion device. We also studied the evolution of testicular adrenal rest tumors (TARTs) and the quality of life through
SF36 survey. Four rates were determined, with a total of 47mg per day. Biochemical parameters were normalizedat 2 months.The
SF36 questionnaire showed a progress of well-being. The weight decreased to 106kg, that is, −5kg (height: 1.71m). Unfortunatly,
there was no change of the TARTs. Two episodes of dermohypodermitis, with abscess at the infusion site, were observed. This case
demonstrates the feasibility of prolonged SCIH therapy in patients with CAH, reporting positive eﬀects on quality of life and on
BMI.
1.Introduction
Congenital Adrenal Hyperplasia (CAH) due to 21-hy-
droxylase deﬁciency is a rare disease with glucocorticoid
and mineralocorticoid deﬁciency. It is due to deletions or
mutations of the cytochrome P450 21-hydroxylase gene
(CYP21), which leads to an excess of ACTH secretion, adre-
nal hyperplasia with accumulation ofsteroidprecursors such
as 17 hydroxyprogesterone (17 OHP) [1]. The main goal of
CAH assessment in adults is to replace deﬁcient steroids in
order to prevent adrenal crises and to suppress the abnormal
secretion of androgens. In addition to ﬂudrocortisone,
different glucocorticoids can be used: prednisolone (BID),
dexamethazone, even if the treatment of choice is hydrocor-
tisone, thrice daily. Despite of this, the adequate replacement
therapy is sometimes diﬃcult to obtain.
Testicular Adrenal Rest Tumors (TARTs) are ACTH-
dependentadrenaltissuescontainedintestis[2].Duetotheir
common embryologic origin, it is supposed that TARTs are
derived from adrenocortical remnants descended with the
testis. They are frequently present in CAH male adults [3]
and seem to reﬂect undertreatment and tobe associated with
a reduced fertility [4]. A gain in fertility has been reported in
this context through a suppressive glucocorticoid treatment
[5].
Recent reports have shown that subcutaneous contin-
uous infusion of hydrocortisone (SCIH) can be used in
patients with adrenal insuﬃciency and CAH to replace
endogenous cortisol production [6–8]. Our case report of
the young CAH man, treated for 2 years, aimed to show
the feasibility of such a prolonged therapy and its possible
beneﬁts, such as a reduction in TARTs volume.
2.Subject andMethods
2.1. Subject. A 27-year-old man with CAH, was followed up
in our centre for 8 years. The disease was diagnosed at age
of 2 weeks, after a salt-losing crisis. Diagnosis was conﬁrmed
later by molecular analysis of CYP21 gene showing 2 large
deletions.
A therapy with ﬂudrocortisone and hydrocortisone was
started. After the development of puberty, the patient’s2 ISRN Endocrinology
treatment compliance decreased. Long periods with no
therapy, and repeated hospitalizations for adrenal crisis were
recorded. He was permanently tired. At the age of 22,
testicular pain revealed the presence of bilateral TARTs. In
this context, analyses showed azoospermia. Despite of our
advice for 4 years, no conservation of sperm had been
done. Volume of TARTs increased. Upon the ultrasound of
the testis, the dimensions of the right testis’s TARTs were
10 × 20 × 30mm, and the left testis’s TARTs showed a
conglomerated, heterogeneous bulk of 49 × 21 × 42mm.
A treatment with dexamethazone was introduced. But it
induced an important weight gain and cutaneous atrophy.
Due to patient’s noncompliance, we observed major melan-
oderma. This noncompliance context, TARTs presence,
and glucocorticoid therapy complications compelled us to
deliver hydrocortisone by a continuous infusion using an
insulin infusion device (Minimed 715, Medtronic Diabetes).
Hemisuccinate of hydrocortisone was used (100mg/mL).
It was diluted to obtain 150mg in 3mL in line with 1UI
on the pump delivering 0.5mg of hydrocortisone. The
basal infusion was set to normalize cortisol concentrations.
Cortisol and 17 OHP were measured every 4h during 24h.
Such patterns were performed before, at day 1, day 8, at 2
months, at year 1 and year 2 from the start of the therapy.
Furthermore, ﬂudrocortisone was delivered at 150µgp e r
day, per os.
We also studied the evolution of TARTs through ultra-
sound, sperm count, and SF36 questionnaire’s health score.
2.2. Assays. Serum total cortisol was measured by chemilu-
minescence (Vidas-Biomerieux). The intra-assay coeﬃcient
of variation (CV) was 3%, and the interassay CV was 5%.
Results were in µg/dl (conversion rate in nmol/L: 27.59).
Total testosterone, 17 OHP and Δ4 androstenedione (Δ4
AD) were measured with a radioimmunological assay (RIA)
(Immunotech). Intra-assay CVs were, respectively, 2, 8, and
8.5%, interassay CVs 12, 9, and 12%.
ACTH,plasmatic reninconcentrationsweremeasuredby
RIA (Cisbio Schering). Intra-assay CVs were, respectively, 6
and 9%, interassay CVs 10 and 5%.
3.Results
Figure 1 shows the used basal infusion rates by the device. A
total of 4 rates were set, ranging from 0.1–1.6mg/h. A total
of 47mg per day was delivered (0.42mg/kg/day). The rates
were unchanged after 2 months of infusion. Table 1 presents
the evolutionof diﬀerent biochemical parameters.
Shortly after the initiation of the hydrocortisone infu-
sion, the patient felt less tired. He was more dynamic, and
made important decisions concerning his professional and
private life (found a stable job, obtained his driving licence,
established a steady and romantic relationship). The SF36
questionnaire, realized before the use of the device, and 1
year after, showed an increase of the well-being (physical
function: from 70 to 95). The weight decreased to 106kg
(−5kg, 1.71m; BMI: 36.25kg/m2).
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Figure 1: Hydrocortisone infusion rates used in the patient
and serum cortisol concentration obtained after 2 months of
hydrocortisone infusion.
Table 1: Eﬀect of hydrocortisone infusion on biochemical param-
eters, before, 2 months and 2 years of hydrocortisone infusion (all
blood samples were taken at 8h; 17 OHP: 17 hydroxyprogesterone,
Δ4 AD: delta 4 androstenedione).
Before 2 months 2 years
Cortisol (µg/dl) (N: 12–25) 1.5 11.2 13.7
17 OHP (ng/mL) (N: <2) 86 24.5 26.5
ACTH (pmol/L) (N: 2–12) 494 15.5 26
Δ4A D( n g / m L )( N: <1.8) 24.6 10.8 16.5
Testosterone (ng/mL) (N: 3–10) 11.8 3.3 7.6
Unfortunatly, despite of the good biological results, there
was no decrease in the TARTs’ volume (the dimensions
remained stable). The azoospermia persisted. Two episodes
of dermohypodermitis, with abscess at the infusion site,
were observed at years 1 and 2 of the start of the infusion.
We reported no episode of illness or big stress imposing to
double the rates. No hospitalization was necessary due to a
possible adrenal crisis.
4.Discussion
In this work, we report the case of a male patient with
CAH who was treated by prolonged subcutaneous infusion
of hydrocortisone. The cortisol circadian delivery rhythm
was obtained quickly, as well as satisfying biological results,ISRN Endocrinology 3
that is, a good CAH control and an increased well-being.
Unfortunatly, after 2 years of SCIH, there was no decrease
of the TARTs volume. Two episodes of dermohypodermitis
were recorded.
T oo u rk n o w l e d g e ,t h i si st h eﬁ r s tc a s er e p o r te v a l u a t i n g
prolonged SCIH therapy in an adult with CAH. Prior
published studies have shown the interest of a circadian
delivery of hydrocortisone in 2 patients with Addison’s
disease, 2 patients with CAH [7], and the technical feasibility
of this hydrocortisone infusion in 7 patients with Addison’s
disease during 12 weeks [6]. More recently, Bryan et al.
reported the case of a young boy treated during 4 years by
SCIH [8]. His therapy made possible a normal progression
of puberty. In these described CAH patients with SCIH, the
hydrocortisone was delivered with an insulin pump, set at 4
or 5 diﬀerent rates. The course of the basal rates was not very
diﬀerent from one patient to another. The maximal reported
rate was 3mg/h. But for our patient, the maximal one was
higher (6mg/h), as well as the total daily dose. This higher
dose could be due to a diﬀerent indication, an older age or
a higher weight. These basal rates were set to be near the
normal secretion rates, as reported in other studies [9].
The use of SCIH induced a fast decrease of the 17
OHP and ACTH levels, as described earlier [7, 8]. These
optimal results persisted for 2 years. In our patient, Δ4A D
levels, decreased at ﬁrst, but remained high despite of the
normalized ACTH concentrations. This was not reported
by Bryan et al. [8]. Furthermore, we found appropriate
levels of total testosterone, despite of the presence of TARTs.
Unfortunatly, we did not measure the progesterone (which
could have inﬂuenced the testosterone production) and
FSH, and did not study the possible conversion of adrenal
androgens through dexamethazone testing.
This therapy was very well tolerated. The patient man-
aged the pump himself. But we noticed two episodes of
dermohypodermitis, with a local abscess at the infusion site.
Similar episodes were reported by Bryan et al., but only one
in 4 years [8]. Local abscess is very rare with infusion of
insulin. It is diﬃcult to know if the infusion of hydrocorti-
sone could enhance such a local complication. The method
to change patient’s catheter with a perfect skin preparation
was revised regularly. Butit did not preventthe apparition of
this skin complication.
TARTs are frequent in young male CAH patients [10]. It
seems they could even appear in subjects with appropriate
treatment compliance but are more frequent in males with
chronic undertreatment [4]. Claahsen-van der Grinten et al.
demonstrated reversing of TARTs, in a man, through a sup-
pressive glucocorticoid treatment [5]. So we hypothesized
that a good hormonal control during 2 years could induce
a decrease in the TARTs therefore reversing the infertility.
Unfortunatly, TARTs remained stable in time. Diﬀerent hy-
potheses could explain this: (a) the intensiﬁcation of gluco-
corticoid treatment may not be always suﬃcient in reducing
the TARTs, as suggested in a study with the hypothesis of
an abnormal control of testis development, independent of
the ACTH stimulation [11]; (b) the duration of the SCIH
could be too short; (c) the lesions in the testicular glands
of our patient could be irreversible [11]. To conﬁrm this
last hypothesis, we suggest an earlier application of SCIH in
youngmaleswith TARTsresponsible ofacompression ofrete
testis and oligospermia due to obstruction of seminiferous
tubules, but without ﬁbrosis.
The use of SCIH seems to have other positive eﬀects.
Despite of therapy’s constraints, we noticed an increase in
our patient’s well-being through the prospectively observed
progression of SF36 health score. Upon morning rise, he was
dynamic and stayed active in his daily tasks. A decreased
quality of life in patients with Addison’s disease or CAH
is well known [12]. The inﬂuence of the mode of the hy-
drocortisone replacement has been noted [13]. Thus, SCIH
therapy capable of mimicking the natural circadian cortisol
production seems to be the best hydrocortisone delivery
mode enhancing quality of life. Furthermore, we reported
patient’s weight loss to be beneﬁcial for most CAH adults
having high BMIs [14]. This reduction of BMI was also
described by Bryan et al. [8].
SCIH represents a new approach to treat CAH. Even
though we did not analyze this treatment mode’s cost, we
would like to emphasize that through a gain in health score
and patient’s well-being, less frequent hospitalization will
be required. This can lead to signiﬁcant savings in national
public health’s budget.
In conclusion, this case demonstrates the feasibility of
prolonged SCIH therapy in patients with CAH. This method
c o u l dh a v ep o s i t i v ee ﬀects on quality of life and on BMI.
Unfortunatly, we did not achieve a decrease of the TARTs.
This method is a new and promising method, with the
aim to control the biochemical parameters, and to diminish
complicationsofCAHandglucocorticoidtreatment.Further
studies are needed to better identify the role and beneﬁts of
this new delivery mode, through a largerselection ofpatients
and comparing this new therapy’s outcomes with those of
conventional therapy.
References
[1] P. C. White and P. W. Speiser, “Congenital adrenal hyperplasia
due to 21-hydroxylase deﬁciency,” Endocrine Reviews, vol. 21,
no. 3, pp. 245–291, 2000.
[ 2 ]J .P .B e r c o v i c i ,J .F i e t ,L .G i b a u l te ta l . ,“ T e s t i c u l a ra d r e n a l
rest tumours insaltwastingcongenitaladrenal hyperplasia (in
vivo and in vitro studies),” Journal of Steroid Biochemistry and
Molecular Biology, vol. 93, no. 1, pp. 67–72, 2005.
[ 3 ]N .M .M .L .S t i k k e l b r o e c k ,B .J .O t t e n ,A .P a s i ce ta l . ,
“High prevalence of testicular adrenal rest tumors, impaired
spermatogenesis, and Leydig cell failure in adolescent and
adult males with congenital adrenal hyperplasia,” Journal
of Clinical Endocrinology and Metabolism, vol. 86, no. 12,
pp. 5721–5728, 2001.
[4] N. Reisch, L. Flade, M. Scherr et al., “High prevalence of
reduced fecundity in men with congenital adrenal hyperpla-
sia,” Journal of Clinical Endocrinology and Metabolism,v o l .9 4 ,
no. 5, pp. 1665–1670, 2009.
[5] H. L. Claahsen-van der Grinten, B. J. Otten, F. C. Sweep, and
A. R. Hermus, “Repeated successful induction of fertility after
replacing hydrocortisone with dexamethazone in a patient
with congenitaladrenal hyperplasia and testicular adrenal rest
tumors,” Fertility and Sterility, vol. 88, pp. 705e5–705e8, 2007.4 ISRN Endocrinology
[6] K.LovasandE.S.Husebye, “Continuoussubcutaneoushydro-
cortisone infusion in Addison’s disease,” European Journal of
Endocrinology, vol. 157, pp. 109–112, 2007.
[ 7 ]Z .M e r z a ,A .R o s t a m i - H o d j e g a n ,A .M e m m o t te ta l . ,“ C i r -
cadian hydrocortisone infusions in patients with adrenal
insuﬃciency and congenital adrenal hyperplasia,” Clinical
Endocrinology, vol. 65, no. 1, pp. 45–50, 2006.
[ 8 ]S .M .B r y a n ,J .W .H o n o u r ,a n dP .C .H i n d m a r s h ,“ M a n -
agement of altered hydrocortisone pharmacokinetics in a
boy with congenital adrenal hyperplasia using a continuous
subcutaneous hydrocortisone infusion,” Journal of Clinical
Endocrinology and Metabolism, vol. 94, no. 9, pp. 3477–3480,
2009.
[9] J. Newell-Price, M. Whiteman, A. Rostami-Hodjegan et al.,
“Modiﬁed-released hydrocortisone for circadian therapy: a
proof-of-principle study in dexamethasone-suppressed nor-
mal volunteers,” Clinical Endocrinology, vol. 68, pp. 130–135,
2008.
[10] N. M. M. L. Stikkelbroeck, B. J. Otten, A. Pasic et al.,
“High prevalence of testicular adrenal rest tumors, impaired
spermatogenesis, and Leydig cell failure in adolescent and
adult males with congenital adrenal hyperplasia,” Journal
of Clinical Endocrinology and Metabolism, vol. 86, no. 12,
pp. 5721–5728, 2001.
[11] H. L. Claahsen-van der Grinten, B. J. Otten, M. M. L. Stikkel-
b r o e c k ,F .C .G .J .S w e e p ,a n dA .R .M .M .H e r m u s ,“ T e s t i c u l a r
adrenal rest tumours in congenital adrenal hyperplasia,” Best
Practice and Research: Clinical Endocrinology and Metabolism,
vol. 23, no. 2, pp. 209–220, 2009.
[12] K. Løv˚ a s ,J .H .L o g e ,a n dE .S .H u s e b y e ,“ S u b j e c t i v eh e a l t h
status in Norwegian patients with Addison’s disease,” Clinical
Endocrinology, vol. 56, no. 5, pp. 581–588, 2002.
[ 1 3 ]M .R i e d e l ,A .W i e s e ,T .H .S c h u r m e y e r ,a n dG .B r a b a n t ,
“Quality of life in patients with Addison’s disease: eﬀects
of diﬀerent cortisol replacement modes,” Experimental and
Clinical Endocrinology, vol. 101, no. 2, pp. 106–111, 1993.
[14] A. Bachelot, G. Plu-Bureau, E. Thibaud et al., “Long-term
outcome of patients with congenital adrenal hyperplasia due
to 21-hydroxylase deﬁciency,” Hormone Research, vol. 67,
no. 6, pp. 268–276, 2007.